CoChat

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Open access
Addeo, Alfredo, Shah, Pankil K., Bordry, Natacha, Hudson, Robert D., Albracht, Brenna, Di Marco, Mariagrazia, Kaklamani, Virginia, Dietrich, Pierre-Yves, Taylor, Barbara S., Simand, Pierre-Francois, Patel, Darpan, Wang, Jing, Labidi-Galy, Intidhar, Fertani, Sara, Leach, Robin J., Sandoval, Jose, Mesa, Ruben, Lathrop, Kate, Mach, Nicolas, Shah, Dimpy P. · 2021 · Cancer Cell
Cited by 226

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.06.009

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 226

Metadata

Authors
Addeo, A., Shah, P. K., Bordry, N., Hudson, R. D., Albracht, B., Di Marco, M., Kaklamani, V., Dietrich, P.-Y., Taylor, B. S., Simand, P.-F., Patel, D., Wang, J., Labidi-Galy, I., Fertani, S., Leach, R. J., Sandoval, J., Mesa, R., Lathrop, K., Mach, N., & Shah, D. P.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-08
Volume
39
Issue
8
Pages
1091-1098.e2
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3174178131
Cited by
226
References
8
FWCI
15.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.